Lazertinib and Amivantamab (Lazcluze and Rybrevant)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Lazcluze plus Rybrevant be reimbursed by public drug plans for the treatment of locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations if certain conditions are met.
• Lazcluze plus Rybrevant should only be covered to treat adults (≥ 18 years) with newly diagnosed NSCLC whose tumours have spread to other parts of the body, returned after treatment, or cannot be removed by surgery or chemoradiation; whose tumours harbour EGFR exon 19 deletions or L858R substitution mutations; and who are in relatively good health.
• Lazcluze plus Rybrevant should only be reimbursed for patients who have not had any prior anticancer treatment for advanced or metastatic disease, if prescribed by clinicians with expertise in treating NSCLC, and the cost of Lazcluze plus Rybrevant does not exceed the total cost of treatment with osimertinib plus platinum-based chemotherapy (PBC).